Y Intercept Hong Kong Ltd Sells 11,899 Shares of Henry Schein, Inc. $HSIC

Y Intercept Hong Kong Ltd lessened its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 57.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,839 shares of the company’s stock after selling 11,899 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Henry Schein were worth $587,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein during the 2nd quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd purchased a new position in Henry Schein during the second quarter valued at $43,000. Evelyn Partners Investment Management Services Ltd bought a new stake in Henry Schein in the second quarter worth $62,000. Finally, Mather Group LLC. bought a new stake in Henry Schein in the third quarter worth $71,000. Institutional investors own 96.62% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the subject of several analyst reports. Morgan Stanley raised their price target on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Evercore ISI upped their target price on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Barrington Research set a $79.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Finally, Barclays assumed coverage on Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Henry Schein has an average rating of “Hold” and an average price target of $76.42.

Henry Schein Stock Down 2.9%

Shares of Henry Schein stock opened at $73.14 on Wednesday. The company has a market cap of $8.61 billion, a price-to-earnings ratio of 23.15, a price-to-earnings-growth ratio of 2.24 and a beta of 0.88. The company’s 50 day moving average is $76.26 and its 200 day moving average is $70.87. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The firm had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.